Profile change history

What changed for Semaglutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Semaglutide identity.

298Total events
290Record additions
8Version changes
10Cited source years

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT06015893

ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.

Cited source date

Before
2026-08-03
After
2026-11-16

Source observed date

Before
2026-08-13
After
2026-11-16

Cited source records

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Headline citations

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Summary citations

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]

Source snapshot commitment

Before
a4aeea2f9b0f59d39a847b4a9aeb5803154bc2def132f9465486d71eee198e5c
After
89b6fa98e2a99b1140238cec416d1f9a55fb79d619a93bb0413e7922c3bc223a
Record updated

Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-17
After
2026-11-01

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Headline citations

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Summary citations

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Attributable context

Before
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
After
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]

Source snapshot commitment

Before
eab353679f205fa5faa1c057fdb6bd19f62c13d6b1d4c1142774b7af3956a42d
After
34b907ddc6cec008126f746b3c051e747e49a7b1a5d931a71ddab936a8fe30cd
Record updated

Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-10
After
2026-10-09

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Headline citations

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Summary citations

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Attributable context

Before
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
After
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]

Source snapshot commitment

Before
40371d4fc303f9890f165794e7bc1cdff3c5d283a74e058cd08dfec64e487e62
After
049db8537e8e0ed1acbba612a8b6e19e7a2b629ebe72c72ef6a452ac2b240137
Record updated

Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 3, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-17
After
2026-11-03

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
After
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

Headline citations

Before
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
After
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

Summary citations

Before
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
After
pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

Attributable context

Before
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
After
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]

Source snapshot commitment

Before
36da0f20323fce8e5f8e5d27c35090369921d8ad1f431ae9084ac66aa6ac558d
After
c20c2731770e88c463b15f02280c8ac57168fe802a51e0365364b5841872ef32
Record updated

ClinicalTrials.gov record NCT06299098

ClinicalTrials.gov posted a newer version of NCT06299098, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

Cited source date

Before
2026-07-21
After
2026-11-12

Source observed date

Before
2026-08-10
After
2026-11-15

Cited source records

Before
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
After
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

Headline citations

Before
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
After
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

Summary citations

Before
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
After
ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]

Source snapshot commitment

Before
5daab950986505011c46590a906c6633448e2a82fecd91776e83eb5058256666
After
ac8b8fbebfec0cf7c2103200aabff05341060cb529bf54ef4662b0b5175d3d73
Profile status changed

Semaglutide profile

We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
U.S. label record
After
FDA-approved as Ozempic, Rybelsus and Wegovy

Profile summary

Before
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
After
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.

Evidence note

Before
The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.

Cited source records

Before
dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity
After
dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813, fda-drugs-nda218316-2025-12-22-e39b0518156a, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]
After
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-unapproved-glp1-concerns-2026-r2]

Claim citations

Before
name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
After
name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-unapproved-glp1-concerns-2026-r2
Profile updated

Semaglutide profile

We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.

PeptideScanner change date
July 29, 2026
Evidence lane
Profile

Related names

Before
Wegovy
After
Wegovy, Ozempic, Rybelsus

Cited source records

Before
dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026
After
dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity

Claim citations

Before
name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
After
name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
Profile updated

Semaglutide profile

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A GLP-1 receptor agonist represented by an exact current Wegovy label record and an FDA notice.
After
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.

Collection chronology

Evidence added to PeptideScanner

Browse all 290 connected records →

Showing the latest 100 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

ClinicalTrials.gov record NCT03596450

PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04916470

PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05254314

PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 1, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05714683

PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 18, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06045221

PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06058585

PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 5, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06706284

PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 5, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06715514

PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06738979

PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06778967

PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06908694

PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 14, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06977438

PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07064486

PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07112872

PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07284979

PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07400107

PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07415954

PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07511543

PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07547878

PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07564414

PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07639021

PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07642635

PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07668388

PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07743983

PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07770841

PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07812597

PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07836140

PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07845578

PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07849348

PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07850765

PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07855133

PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07858331

PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 5, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07871799

PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07879612

PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 19, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07881770

PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 19, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07891156

PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07900438

PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07909889

PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07911046

PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07931573

PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07931599

PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07935200

PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Record added

Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee.

PubMed lists PMID 42722400 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
September 10, 2026
Evidence lane
Literature metadata
Record added

Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism.

PubMed lists PMID 42754946 in Acta psychiatrica Scandinavica as Letter, with publication-date metadata of 2026-09-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
September 18, 2026
Evidence lane
Literature metadata
Record added

Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications.

PubMed lists PMID 42769283 in Cureus as Editorial, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
September 23, 2026
Evidence lane
Literature metadata
Record added

Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.

PubMed lists PMID 42785112 in The journal of prevention of Alzheimer's disease as Journal Article, Review, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 7, 2026
Evidence lane
Literature metadata
Record added

Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose.

PubMed lists PMID 42823892 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 2, 2026
Evidence lane
Literature metadata
Record added

Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.

PubMed lists PMID 42862749 in Cardiology as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 12, 2026
Evidence lane
Literature metadata
Record added

GLP-1s and criminality: US trial will test whether semaglutide can fight crime.

PubMed lists PMID 42901618 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 20, 2026
Evidence lane
Literature metadata
Record added

Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population.

PubMed lists PMID 42946801 in Journal of gastroenterology as Editorial, with publication-date metadata of 2026-10-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 28, 2026
Evidence lane
Literature metadata
Record added

Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.

PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 3, 2026
Evidence lane
Literature metadata
Record added

Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use.

PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

Semaglutide and alcohol use disorder: An evidence gap India must fill.

PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT03811561

PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
September 9, 2026
Cited source date
September 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07662213

PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
September 9, 2026
Cited source date
September 9, 2026
Evidence lane
Clinical trials
Record added

"I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising.

PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
September 9, 2026
Evidence lane
Literature metadata
Record added

Ozempic and thin line between therapy and dependence.

PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
September 7, 2026
Evidence lane
Literature metadata
Record added

Off-label semaglutide: A call for monitoring protocols in non-obese populations.

PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
September 7, 2026
Evidence lane
Literature metadata
Record added

FDA enforcement report D-0536-2021

FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
June 2, 2021
Evidence lane
Safety
Record added

Semaglutide DailyMed SPL version 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
June 7, 2021
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 10

DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
December 12, 2024
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 11

DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
August 29, 2025
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 12

DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 17, 2025
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 13

DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
December 5, 2025
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 14

DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
January 6, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 15

DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 12, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 16

DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 5, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 17

DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
April 2, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 18

DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
May 22, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 19

DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
June 30, 2026
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 2

DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 11, 2022
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 3

DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
January 9, 2023
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 4

DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 27, 2023
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 5

DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 8, 2023
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 6

DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
August 1, 2023
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 7

DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 18, 2024
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 8

DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
April 12, 2024
Evidence lane
Regulatory
Record added

Semaglutide DailyMed SPL version 9

DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 15, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 2017-21176

The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
October 3, 2017
Evidence lane
Regulatory
Record added

Federal Register notice 2019-25850

The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
November 29, 2019
Evidence lane
Regulatory
Record added

Federal Register notice 2020-04320

The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
March 3, 2020
Evidence lane
Regulatory
Record added

Federal Register notice 2021-18072

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
August 23, 2021
Evidence lane
Regulatory
Record added

Federal Register notice 2023-25485

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
November 17, 2023
Evidence lane
Regulatory
Record added

Federal Register notice 2025-19345

The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
October 2, 2025
Evidence lane
Regulatory
Record added

Federal Register notice 2025-22131

The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

PeptideScanner change date
August 21, 2026
Cited source date
December 5, 2025
Evidence lane
Regulatory
Record added

Federal Register notice 2026-02786

The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
February 12, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-03963

The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
February 27, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-08435

The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
April 30, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-08552

The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
May 1, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-12937

The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
June 26, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-15285

The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

PeptideScanner change date
August 21, 2026
Cited source date
July 29, 2026
Evidence lane
Regulatory
Record added

Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.

PubMed lists PMID 40850442 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
June 26, 2026
Evidence lane
Literature metadata
Record added

Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.

PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
June 26, 2026
Evidence lane
Literature metadata
Record added

Secondary alopecia due to semaglutide.

PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
June 27, 2026
Evidence lane
Literature metadata
Record added

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
August 15, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT03884075

PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07087795

PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 13, 2026
Evidence lane
Clinical trials